Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4204976 | 0.77 | PKM (0.47) | PSIP1CA12CA2CA9HSP90AA1 | |
| SCHEMBL4980683 | 0.77 | NR3C2 (0.41) | CA12CA2CA9HSP90AA1ESR1 | |
| SCHEMBL13762630 | 0.76 | CA12 (0.50) | PSIP1CA12CA2CA9HSP90AA1 | |
| SCHEMBL17333643 | 0.74 | ESR1 (0.56) | ESR1TSHRALDH1A1GLATDP1 | |
| SCHEMBL28347318 | 0.74 | PSIP1 (0.41) | PSIP1CA12CA2CA9HSP90AA1 | |
| SCHEMBL9453750 | 0.73 | TSHR (0.42) | CA12CA2CA9HSP90AA1ESR1 | |
| SCHEMBL7724496 | 0.72 | TSHR (0.44) | PSIP1CA12CA2CA9HSP90AA1 | |
| SCHEMBL17333403 | 0.72 | ESR1 (0.60) | ESR1TSHRTDP1TP53KMT2A | |
| SCHEMBL5281575 | 0.71 | APOBEC3G (0.52) | CA12CA2CA9ESR1TSHR | |
| SCHEMBL5012326 | 0.71 | ESR1 (0.41) | PSIP1CA12CA2CA9HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020010202-A1 | Combinations of prostaglandins and brimonidine or derivatives thereof | ALLERGAN SALES, INC. | 2002-01-24 | — | — | US | claimed |
| US-6294563-B1 | PROTECTION OF NERVES AND TREATING GLAUCOMA OR OCULAR HYPERTENSION | ALLERGAN SALES, INC. | 2001-09-25 | — | — | US | claimed |
| WO-1996013267-A2 | COMBINATIONS OF PROSTAGLANDINS AND BRIMONIDINE OR DERIVATIVES THEREOF FOR THE TREATMENT OF GLAUCOMA | ALLERGAN (US) | 1996-05-09 | — | — | WO | claimed |
| US-20020010202-A1 | Combinations of prostaglandins and brimonidine or derivatives thereof | ALLERGAN SALES, INC. | 2002-01-24 | — | — | US | disclosed |
| US-6294563-B1 | PROTECTION OF NERVES AND TREATING GLAUCOMA OR OCULAR HYPERTENSION | ALLERGAN SALES, INC. | 2001-09-25 | — | — | US | disclosed |
| WO-1996013267-A2 | COMBINATIONS OF PROSTAGLANDINS AND BRIMONIDINE OR DERIVATIVES THEREOF FOR THE TREATMENT OF GLAUCOMA | ALLERGAN (US) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010202-A1 | Combinations of prostaglandins and brimonidine or derivatives thereof | PTGER1, ADRB2, PTGS1 | PSIP1 1920/4885CA12 3114/4885CA2 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.